This ‘Strong Buy’ Pharma Stock Is Surging to New Highs

Insmed (INSM) shows strong technical momentum, hitting a new 52-week high on Aug. 18.

INSM has a 100% “Buy” opinion from Barchart with impressive recent gains.

Revenue is projected to grow nearly 29% this year and 126% next year, with earnings growth expected to accelerate in 2026.

Wall Street analysts are mostly bullish, but there is a wide range of price targets on INSM here.

Valued at $26.9 billion, Insmed (INSM) is a biopharmaceutical company engaged in the development and commercialization of ARIKAYCE, or liposomal amikacin for inhalation, for at least two identified orphan patient populations. The group is patients with non-tuberculous lung infections. The second is cystic fibrosis patients with Pseudomonas aeruginosa lung infections. Insmed is also focused on the development of INS1009, an inhaled treatment for pulmonary arterial hypertension.

I found today’s Chart of the Day by using Barchart’s powerful screening functions to sort for stocks with the highest technical buy signals; superior current momentum in both strength and direction; and a Trend Seeker “buy” signal. I then used Barchart’s Flipcharts feature to review the charts for consistent price appreciation. INSM checks those boxes. Since the Trend Seeker signaled a buy on June 3, the stock gained 74.15%.

INSM Price vs. Daily Moving Averages:

www.barchart.com

Editor’s Note: The technical indicators below are updated live during the session every 20 minutes and can therefore change each day as the market fluctuates. The indicator numbers shown below therefore may not match what you see live on the Barchart.com website when you read this report. These technical indicators form the Barchart Opinion on a particular stock.

Insmed shares hit a new 52-week high on Aug. 18, touching $130.13 in intraday trading.

Insmed has a Weighted Alpha of +67.81.

INSM has an 100% “Buy” opinion from Barchart.

The stock gained 64.02% over the past year.

INSM has its Trend Seeker “Buy” signal intact.

Insmed is trading above its 20-, 50-, and 100-day moving averages.

The stock made 15 new highs and gained 24.09% in the last month.

Relative Strength Index (RSI) is at 83.71%.

There’s a technical support level around $126.22.

Story Continues

$26.9 billion market capitalization.

Revenue is projected to grow 28.82% this year and another 126.13% next year.

Earnings are estimated to increase 0.35% this year and an additional 29.14% next year.

I don’t buy stocks because everyone else is buying, but I do realize that if major firms and investors are dumping a stock, it’s hard to make money swimming against the tide.

It looks like Wall Street analysts are bullish on INSM, but CFRA’s MarketScope Advisor is not.

The Wall Street analysts tracked by Barchart have issued 16 “Strong Buy,” 1 “Moderate Buy,” and 1“Hold” opinion on the stock.

Their price targets are between $110-$240 – a very wide spread.

Value Line gives the stock its average rating.

CFRA’s MarketScope Advisor gives the stock a “Sell” rating.

Morningstar thinks the stock is fairly valued.

352 individual investors on Motley Fool think the stock will beat the market while 108 think it won’t.

4,010 investors monitor the stock on Seeking Alpha, which rates the stock a “Hold.”

Insmed currently has momentum and is hitting new highs.

I caution that INSM is volatile and even speculative in the current environment, which means investors should use strict risk management and stop-loss strategies.

Today’s Chart of the Day was written by Jim Van Meerten. Read previous editions of the daily newsletter here.

Additional disclosure: The Barchart of the Day highlights stocks that are experiencing exceptional current price appreciation. They are not intended to be buy recommendations as these stocks are extremely volatile and speculative. Should you decide to add one of these stocks to your investment portfolio it is highly suggested you follow a predetermined diversification and moving stop loss discipline that is consistent with your personal investment risk tolerance.

On the date of publication, Jim Van Meerten did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com

Source link